The world’s best preclinical neuroscience
For more than 30 years, in collaboration with some of the best partners in the world, Atuka’s scientists have continued to advance both knowledge and research techniques in the field of Parkinson’s disease and beyond.
BEHIND THE SCIENCE
-
Parkinson’s disease prevalence is soaring—but is there a good news story hidden in the data?
As Parkinson’s becomes the fastest-growing neurological disorder worldwide, its rising prevalence raises urgent questions about public health and economic impact. Could improved diagnosis, treatment, and life expectancy offer a hidden silver lining within the statistics?
-
Highlights from Neuroscience 2024
At the annual summit of the Society for Neuroscience in Chicago, it was clearer than ever that collaboration and advancing technologies are central to moving the field forward.
-
New frontiers in inflammasome therapeutics
Insights from Atuka’s recent visit to the 6th Annual Inflammasome Summit in Boston.
-
What the market overlooked in Seelos’s recent trehalose study
Atuka’s Jonathan Brotchie and Patrick Howson take a deeper look at the top-line results for IV trehalose, an ALS treatment, and see signs of potential for the compound that the market may have missed.
-
Tavapodon offers great promise as a new therapeutic for Parkinson’s disease
On the encouraging topline results from Cerevel Therapeutics’ Phase III TEMPO-3 trial for tavapadon, a D1/D5 dopamine receptor partial agonist.
WHITE PAPER
The future of gene therapy from a pre-clinical perspective
The potential of gene therapies is finally being realized and these therapies can deliver life-changing treatments for a broad range of disorders.
Atuka’s Chief Innovation Officer Dr Patrick A. Howson explores the past, present, and future of gene therapy.
Published papers
Atuka’s scientists have been publishing groundbreaking neuroscience research for many decades, often in collaboration with other renowned leaders in our field. The peer-reviewed papers collected below track the evolution of both our ongoing research and the field more broadly.
-
/ 104 Citations -
/ 19 Citations -
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat
/ 25 Citations -
Management of impulse control disorders in Parkinson’s disease: Controversies and future approaches
/ 89 Citations -
/ 6 Citations -
Monoamine Reuptake Inhibitors in Parkinson’s Disease
/ 17 Citations -
/ 72 Citations -
/ 39 Citations -
The Opioid System in Levodopa-Induced Dyskinesia
/ 0 Citation -
Symptomatic Models of Parkinson’s Disease and L-DOPA-Induced Dyskinesia in Non-human Primates
/ 21 Citations -
/ 37 Citations -
Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit
/ 55 Citations -
/ 11 Citations -
/ 36 Citations -
/ 20 Citations -
/ 43 Citations -
/ 5 Citations -
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
/ 268 Citations -
Novel nondopaminergic targets for motor features of Parkinson’s disease: Review of recent trials
/ 100 Citations -
/ 19 Citations
TALK TO OUR EXPERTS